CASP3 and cancer: Our work reveals that prolonged pharmacologic blockade of A2A receptors with ZM241385 results in a discrete but significant reduction in the cell viability in conjunction with higher caspase-3 activity, suggesting an antiproliferative effect in cancer cells for A2A receptor antagonists.